Academy Capital Management Has $14.06 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Academy Capital Management cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,013 shares of the company’s stock after selling 159 shares during the period. IDEXX Laboratories accounts for 2.3% of Academy Capital Management’s portfolio, making the stock its 11th largest holding. Academy Capital Management’s holdings in IDEXX Laboratories were worth $14,062,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Farther Finance Advisors LLC raised its stake in IDEXX Laboratories by 15.0% in the third quarter. Farther Finance Advisors LLC now owns 805 shares of the company’s stock valued at $407,000 after buying an additional 105 shares during the period. Chicago Partners Investment Group LLC increased its holdings in shares of IDEXX Laboratories by 16.7% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after acquiring an additional 96 shares during the last quarter. Van ECK Associates Corp raised its stake in IDEXX Laboratories by 10.4% in the 3rd quarter. Van ECK Associates Corp now owns 25,133 shares of the company’s stock valued at $12,698,000 after acquiring an additional 2,367 shares during the period. National Pension Service lifted its holdings in IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock valued at $93,957,000 after purchasing an additional 12,647 shares during the last quarter. Finally, Asset Management One Co. Ltd. boosted its position in IDEXX Laboratories by 1.4% during the third quarter. Asset Management One Co. Ltd. now owns 49,787 shares of the company’s stock worth $25,153,000 after purchasing an additional 707 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Trading Up 1.0 %

Shares of NASDAQ:IDXX opened at $441.61 on Wednesday. The business’s 50 day simple moving average is $436.35 and its 200 day simple moving average is $450.43. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $574.94. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market capitalization of $35.92 billion, a P/E ratio of 41.39, a P/E/G ratio of 3.41 and a beta of 1.37.

Insider Activity

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Finally, Leerink Partners initiated coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.